Discover effective integrative therapies for cognitive decline to support cognitive function and overall brain wellness.

Abstract

In this comprehensive educational post, I walk you through a clear, evidence-based approach to Alzheimer’s disease, from accurate diagnosis using AT(N) biomarkers to a stepwise, targeted pharmacologic plan for cognitive and neuropsychiatric symptoms, and a careful, criteria-driven pathway to disease-modifying therapies. I discuss when to consider blood-based biomarkers, cerebrospinal fluid (CSF) analysis, PET imaging, and genetic testing, particularly in the context of emerging anti-amyloid treatments. I explain why most brains in older adults harbor multiple co-existing neuropathologies and how this reality impacts treatment choices. I highlight the 2025 Alzheimer’s Association–supported DetectAD clinical practice guidance, emphasizing patient-centered communication and shared decision-making. I present practical, physiologic rationales for each therapeutic choice, including acetylcholinesterase inhibitors and memantine, and explain how to interpret modest drug effects on measures like the MMSE, CDR-SB, and ADAS-Cog in the real world. I also detail how we manage neuropsychiatric symptoms, the role of pharmacogenetic testing, and the evolving Alzheimer’s pipeline.

Throughout, I show how our multidisciplinary model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, integrates chiropractic care, functional medicine, personal injury care, and rehabilitation under the medical direction of Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933). I share how we coordinate risk-factor modification, autonomic and vestibular optimization, gait and balance rehabilitation, pain modulation, sleep restoration, and caregiver support alongside medications. This is a translational guide grounded in contemporary research methods and my clinical observations across neurology, internal medicine, and integrative chiropractic practice.

Introduction: My Role, Our Team, and Our Integrative Mission

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. For more than two decades, I have worked at the intersection of musculoskeletal medicine, neurorehabilitation, functional medicine, and personal injury care. At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, I lead an integrative care team with medical direction provided by Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas has over 40 years of experience as an internist and serves as our Medical Director and Collaborative Physician. This multidisciplinary setup—an MD providing medical oversight alongside a chiropractor—is common in modern integrative and injury clinics and is essential when navigating complex, evolving conditions like cognitive decline and dementia syndromes.

In our clinic, I blend integrative chiropractic care with functional diagnostics, physical medicine and rehabilitation, neurocognitive screening, and evidence-based lifestyle therapeutics. Under Dr. Cardenas’s medical guidance, we coordinate structural neuroimaging, laboratory evaluation, pharmacotherapy, and referrals to neuropsychology and neurology as indicated. Together, we ensure our patients receive a safe, medically supervised pathway that respects their values, improves function, and optimizes brain-health outcomes. My perspective is guided by leading research, collaborative ethics, and patterns I have shared across my professional platforms, including observations cataloged on healthcoach.clinic and in my LinkedIn profile.

About Our Integrated Care Team in El Paso

• Medical Director and Collaborative Physician: Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine (NPI #1164426749; Texas MD License #J2933), with over 40 years of experience. She supervises medical evaluation, differential diagnosis, medication safety, cardiometabolic risk stratification, and eligibility for advanced diagnostics and disease-modifying therapies.
• Integrative Chiropractic and Functional Medicine: I, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, oversee musculoskeletal care, autonomic regulation, vestibular and gait rehabilitation, nutrition, sleep optimization, inflammation control, and coordination with physical therapy and behavioral health. My clinical observations and insights are further detailed at healthcoach.clinic and on my professional profile on LinkedIn.
• Multidisciplinary services: Internal medicine, chiropractic care, functional medicine, personal injury medicine, rehabilitation therapy, cognitive screening, care navigation, and caregiver support.

Why Read This Post

• You will learn how to connect AT(N) biomarkers to real-world prescribing.
• You will see when to prioritize symptomatic control versus disease modification.
• You will understand how integrative chiropractic care indirectly supports cognition by reducing pain, improving sleep, restoring autonomic balance, and preventing falls.
• You will gain tools to talk with patients and caregivers about what to expect and why timing matters.

Important Note on Scope

This educational post focuses primarily on Alzheimer’s disease within the dementia spectrum, while acknowledging mixed pathologies, Lewy body disease, vascular injury, and limbic-predominant age-related TDP-43 encephalopathy (LATE). Where relevant, I explain how each factor shapes therapy choices and safety monitoring.

A Structured Diagnostic Pathway: DX before TX

Under Dr. Cardenas’s medical direction, our workflow applies staged decision points. I always start with a thorough, narrative symptom history and a secondary historian. In cognitive disorders, patients often cannot reliably report patterns, timing, or consequences. A trusted partner—spouse, adult child, sibling, close friend, or coworker—can fill in the gaps and reveal unnoticed changes in performance, behavior, or safety.

Step 1: Patient-Centered Foundations and Clinical History

What I ask and why:

• Onset and time course: Did symptoms start abruptly or insidiously? A stepwise decline raises suspicion for a cerebrovascular contribution, while a gradual decline suggests neurodegeneration. Fluctuations may hint at delirium-prone states, sleep fragmentation, medication effects, or Lewy body disorders.
• Symptom quality: Amnestic (memory-first) versus dysexecutive (planning/attention-first) profiles distinguish early Alzheimer’s phenotypes from those associated with frontal or subcortical processes.
• Context and triggers: Stress, illness, travel, anesthesia, and sleep loss can unmask impairment. Inflammatory, metabolic, or hypoxic stressors often worsen cognition.
• What helps, what worsens: Exercise, sleep regularity, social engagement, and structured routines support attention and memory; polypharmacy, anticholinergics, sedatives, unaddressed pain, and sleep disorders often exacerbate deficits.
• Associated neuropsychiatric features: Anxiety, depression, apathy, irritability, hallucinations, delusions, REM behavior disorder, or impulse dyscontrol inform differential diagnosis and care planning.
• Functional status: I ask about instrumental activities of daily living (IADLs), such as managing finances, medications, shopping, cooking, and transportation, as well as basic ADLs like dressing and bathing. Loss of independence signals a transition from mild cognitive impairment (MCI) to dementia.
• Safety: Getting lost, kitchen mishaps, falls, medication errors, financial vulnerability, and driving performance must be reviewed with specificity.

I document at least one example for each reported issue. A subtle real-world error often reveals far more than a numerical test score.

Step 2: Building the Examination Strategy

I perform a focused neurological exam, anticipating that it may be normal early on. I am looking for asymmetry, parkinsonism, upper motor neuron signs, cerebellar dysfunction, sensory loss, gait disturbance, and eye movement abnormalities. These findings narrow the differential and highlight the need for neuroimaging, a vascular workup, or a movement disorder referral.

• Cognitive screening: I use validated tools like the Mini-Cog, the Montreal Cognitive Assessment (MoCA), or a well-validated digital cognitive assessment to establish a baseline and track change. Reliable instruments detect small but meaningful changes, help stage function, and support accurate ICD-10 coding.
• Neuropsychiatric screening: I use tools such as the PHQ-2/PHQ-9 and GAD-7 as directional indicators. For dementia-focused assessment, I prefer, when available, neuropsychiatric inventories tailored to cognitive disorders to improve accuracy.
• Neuropsychological testing: Neuropsychological evaluation remains a cornerstone. Patterned deficits across memory, language, visuospatial, processing speed, and executive domains clarify diagnosis and guide practical recommendations.

Step 3: Imaging and Labs

• Structural neuroimaging: I begin with a brain MRI without contrast when possible. I am looking for atrophy patterns (medial temporal, parietal), white matter disease, strategic infarcts, subdural collections, hydrocephalus, or neoplasm.
• Tier 1 laboratory tests: I ensure that recent labs include CBC, CMP, TSH, vitamin B12, and inflammatory markers, as appropriate. Thyroid dysfunction, B12 deficiency, anemia, and inflammatory states are frequent, reversible contributors to cognitive symptoms. We correct these foundational issues before considering advanced biomarkers.

Step 4: Reversible Contributors

We conduct a thorough medication review for anticholinergic burden, sedative-hypnotics, opioids, antihistamines, bladder antimuscarinics, and polypharmacy interactions.

Step 5: Diagnosis and Staging

I translate functional and cognitive findings into clear stages: Unimpaired, Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), or Dementia (major neurocognitive disorder), staged as mild, moderate, or severe. I then specify the cognitive-behavioral syndrome (e.g., amnestic, dysexecutive) and probable etiology (e.g., Alzheimer’s disease, vascular, mixed). This staging shapes driving recommendations, medication management, fall risk planning, and eligibility for therapies.

Communication, Consent, and Shared Planning: The 2025 DetectAD Guidance

In 2025, an Alzheimer’s Association–supported expert group published the DetectAD clinical practice guidance to standardize and elevate care. It places communication and patient preference at the center of evaluation and treatment.

Core Elements I Implement in Clinic:

• Clear expectations: I explain each step of evaluation, what we might find, and how results could affect choices.
• Secondary historian involvement: I invite a trusted person, with the patient’s permission, to participate in the process to improve accuracy.
• Respect for choice: Just because a test exists does not mean a patient wants it. I present trade-offs honestly.
• Shared care plans: Findings are communicated to both the patient and care partner, and goals are set together.
• Tiered testing: I start with history, exam, functional assessment, validated cognitive tools, labs, and structural imaging—and only then consider advanced biomarkers.
• Staging and coding: I classify as unimpaired, subjective cognitive decline, MCI, or dementia (mild, moderate, severe), then apply ICD-10 coding with the cognitive-behavioral syndrome and likely etiology.

The Evolving Science of Alzheimer’s Disease Biomarkers

Our understanding of Alzheimer’s disease has shifted from a purely symptom-based diagnosis to a biologically anchored model. My own clinical experience mirrors what leading researchers such as Clifford Jack and colleagues have modeled: a decades-long biochemical trajectory in which amyloid dysregulation appears early, followed by tau pathology, neuronal injury, and then clinical impairment.

Key Concept: The Biomarker Cascade

• Beta-amyloid (A?) dysmetabolism precedes tauopathy; soluble A? species and then insoluble plaques accumulate. Tau hyperphosphorylation follows, forming intracellular neurofibrillary tangles.
• Neurodegeneration—synaptic dysfunction, neuronal loss, and network disconnection—emerges as a downstream effect.
• Clinical symptoms manifest only after substantial neuronal reserve has been eroded, often 15–20 years into the process. This order matters because disease-modifying therapies targeting amyloid are most rational before extensive tau-driven neurodegeneration has occurred.

The AT(N) Framework in Practice

• A: Amyloid positivity (PET or CSF; plasma assays increasingly useful as triage tools)
• T: Tau pathology (CSF p-tau, tau PET; select plasma p-tau species correlating with amyloid and tau burden)
• N: Neurodegeneration (MRI atrophy patterns, FDG-PET hypometabolism, and emerging plasma markers such as NfL and GFAP)

A targeted, stepwise diagnostic pathway using this framework reduces misclassification and improves shared decision-making about DMT timing and risks.

Advanced Biomarker Strategies

When clinical suspicion for AD persists and results will change management, we consider escalating testing under Dr. Cardenas’s medical direction.

• Blood-based biomarkers (e.g., plasma A?42/40 ratio, p-tau species, neurofilament light) and CSF analysis can characterize Alzheimer’s pathology in vivo.
• Amyloid PET and tau PET add specificity in select scenarios.
• Genetic testing (e.g., APOE genotyping) may help when contemplating amyloid-targeted therapies and assessing risk, but must be embedded in shared decision-making.

We escalate testing for atypical presentations, early-onset cases, or when decisions hinge on pathological confirmation (e.g., consideration of monoclonal antibodies).

Symptom Context and Mixed Neuropathologies

When I evaluate cognitive complaints, I align the symptom pattern to likely etiologies:

• Memory-predominant with insidious onset and poor recall despite cues: suggests Alzheimer’s pathology.
• Executive slowing, attentional fluctuations, and early visuospatial deficits: consider Lewy body disease or vascular contributions.
• Language-predominant syndromes: consider primary progressive aphasia variants.
• Early behavioral and personality changes: consider the frontotemporal dementia spectrum.

Autopsy and cohort studies reveal that many older adults accumulate multiple pathologies—including amyloid plaques, tau tangles, micro- and macroinfarcts, Lewy bodies, and TDP-43 pathology. In our clinic, we routinely prepare families for this reality: the brain does not “pick one disease.” This poly-etiology means a single drug rarely addresses all symptoms. Vascular risk management is essential even when AD biomarkers are positive because cerebrovascular injury lowers the threshold for symptom onset.

Evidence-Based Outcomes in Dementia: Making Sense of the Measures

In clinical trials and practice, we rely on standardized tools to measure change. Understanding these instruments helps set realistic expectations.

Key Global Measures

• MMSE (Mini-Mental State Examination): A 30-point brief screening. A 1-point change over 6 months in placebo groups is common in mild-to-moderate AD. Treatment groups might show small improvements or less decline, indicating a modest effect aimed at slowing progression.
• CDR (Clinical Dementia Rating) and CDR-SB (CDR Sum of Boxes): The CDR is a structured interview rating function across six domains. Global CDR stages (0–3) are excellent for staging, and the CDR-SB (0–18) offers sensitivity to within-stage change.
• ADAS-Cog (Alzheimer’s Disease Assessment Scale–Cognitive Subscale): A performance-based cognitive battery sensitive to change in early AD trials; higher scores indicate worse impairment.

How I Translate Small Effects into Care Plans

I counsel families: “We aim to slow decline. Dramatic improvement is unlikely.” We place equal weight on functional outcomes like ADLs/IADLs, caregiver hours, falls, agitation, and sleep. We document baseline scores and repeat them every 6–12 months, pairing numeric outcomes with real-world anchors like dressing, meal prep, and money management.

Pharmacologic Strategy for Cognitive Symptoms: Why and How

Cholinergic augmentation and glutamatergic modulation remain core symptomatic treatments. Their primary benefit is slowing decline; they don’t reverse disease.

Cholinesterase Inhibitors (ChEIs): Donepezil, Rivastigmine, Galantamine

• Why they work: AD reduces cholinergic projections from the basal forebrain, impairing attention and memory. By inhibiting acetylcholinesterase, these drugs increase synaptic acetylcholine levels, improving network signal-to-noise ratio and attention.
• Who benefits: Patients with mild to moderate AD; sometimes continued into severe stages. Reasonable benefit in some mixed AD/Lewy presentations.
• Dosing and tolerability: I start low and titrate slowly to mitigate GI effects. Transdermal rivastigmine can help patients with GI sensitivity.
• Safety considerations Include Bradycardia, syncope risk in frail adults, and weight loss. Dr. Cardenas reviews cardiac history and interacting medications. If lightheadedness or syncope emerges, we re-evaluate and consider discontinuation.

Memantine (NMDA Receptor Antagonist)

• Why it works: Pathologic glutamatergic tone drives excitotoxicity and synaptic loss. Memantine reduces this “noise” while preserving physiologic signaling, thereby aiding cognition and behavior in moderate-to-severe stages.
• Who benefits: Patients with moderate to severe AD and mixed etiologies with agitation or psychosis.
• Evidence profile: Memantine’s strongest signal is functional: improving ADLs and reducing caregiver time.
• Dosing pearls: Renal dosing adjustments are needed as required. We often combine it with ChEIs for a complementary effect.

Combination Therapy: Doing Better on Function

• Rationale: AChEIs support cholinergic signaling; memantine moderates excitotoxicity. Together, they target complementary pathways.
• Clinical pattern: Trials show the least decline in MMSE and the best preservation of ADLs occurs in the combination group. This often translates into fewer hours of hands-on care and greater daily autonomy.
• Pragmatics: I titrate AChEIs first, assess tolerance, then add memantine, monitoring for dizziness or changes in alertness.

Setting Expectations with Patients and Families

I explain that these medications can slow decline relative to no treatment over 6–12 months, but dramatic improvements are not expected. We weigh small benefits against side effects like syncope or weight loss. If risks outweigh benefits, deprescribing is appropriate and compassionate.

Pharmacologic Strategy for Neuropsychiatric Symptoms: Precision and Caution

Neuropsychiatric symptoms (NPS) often drive caregiver strain. Our approach pairs nonpharmacologic plans with careful medication choices. Most validated tools rely on care partner reports, which is why a secondary historian is crucial.

Tools We Use and Why

• Neuropsychiatric Inventory (NPI): A caregiver-reported instrument that quantifies symptom frequency and severity.
• Revised Memory and Behavior Problems Checklist (RMBPC): Captures common disruptive behaviors and the caregiver’s reaction.

How We Avoid “Lazy Prescribing”

We always investigate the “why” behind a behavior. Pacing may signal agitation, anxiety, urinary urgency, or pain—each requiring a different intervention. We check for physical drivers like pain, constipation, infection, or medication side effects before adding psychotropic drugs.

Nonpharmacologic Strategies We Emphasize First

• Pain management: Gentle manual therapy and mobility work can reduce nociceptive input that fuels agitation.
• Consistent routines: Fixed schedules for sleep, meals, and activities reduce anxiety.
• Sensory optimization: Ensure glasses and hearing aids are used; improve lighting to limit misperceptions.
• Environmental calibration: Calm spaces, soothing music, and morning light exposure help regulate arousal.
• Communication coaching: Use short sentences, validate feelings, and redirect with meaningful tasks.

Pharmacologic Ladder for NPS

• Depression and apathy: We prefer SSRIs with lower anticholinergic burden. We address sleep, pain, and social isolation first.
• Anxiety and agitation: We avoid benzodiazepines due to fall risks. Low-dose SSRIs or trazodone for sleep can be useful. Chiropractic pain management can substantially reduce agitation by removing nociceptive drivers.
• Psychosis: In Lewy body disease, we use extreme caution with antipsychotics. Memantine and ChEIs may reduce hallucinations in some cases.
• Sleep disturbance: We correct circadian disruption with light and activity scheduling. Pain reduction via conservative care is central to reducing nocturnal awakenings.

Pharmacogenetic Testing: Why We Do It Early

Traditional trial-and-error for antidepressants or antipsychotics can consume months. Pharmacogenetic panels guide selection and dosing based on metabolic and receptor sensitivities, helping us choose a better first- or second-line option and achieve faster stabilization.

Disease-Modifying Therapies Targeting Amyloid: Who, When, and Why

Anti-amyloid monoclonal antibodies (aducanumab, lecanemab, donanemab) represent a major shift in Alzheimer’s care, but they require accurate biomarker confirmation and meticulous safety monitoring.

Rationale and Context

After over a decade of trials with a low success rate, the approval of these agents was a momentous event. Their mechanism is to clear amyloid plaques and reduce soluble toxic species, which may slow downstream tauopathy and neurodegeneration. However, their clinical impact is measured as “slowing decline,” not reversal. This nuance is critical for setting realistic expectations with families.

Key Agents and Their Differences

• Aducanumab: Received accelerated approval for robustly reducing amyloid plaques, but its cognitive benefit was inconsistent across trials. It taught us that biomarker success doesn’t guarantee clinical improvement and highlighted the risk of ARIA.
• Lecanemab and donanemab: These agents demonstrated a statistically significant slowing of clinical decline in early-stage, biomarker-confirmed AD. Lecanemab slowed decline on the CDR-SB over 18 months, while donanemab also showed slowed decline, with some evidence of reduced ARIA at lower doses.

Selection Criteria for Anti-Amyloid Therapies

• Confirmed A+ status: Amyloid positivity must be confirmed by PET or CSF; blood tests often serve as triage tools.
• Clinical stage: MCI due to AD or mild AD dementia typically show the most benefit.
• MRI screening: A baseline MRI is essential for detecting microhemorrhages and leukoaraiosis and for assessing ARIA risk.
• APOE ?4 carrier status: This genetic factor significantly increases ARIA risk, especially for ?4/?4 homozygotes. Informed consent must include a detailed discussion of this risk.

Safety and Monitoring for ARIA

ARIA (amyloid-related imaging abnormalities) can manifest as edema (ARIA-E) or hemorrhage (ARIA-H). While often asymptomatic, ARIA can cause headache, confusion, nausea, or gait changes, and in rare cases, can be serious.

• Updated MRI Timing: Registry data and evolving appropriate use recommendations suggest that adding an MRI after the second infusion can detect serious ARIA earlier. Our clinic has adopted this as a standard safety measure.
• Monitoring Framework: We conduct a pre-treatment MRI, followed by MRIs before several early infusions. We also use a symptom checklist at every infusion and have an immediate escalation pathway for any new neurologic symptoms. Dr. Cardenas directs our protocolized imaging and symptom surveillance.

Access, Logistics, and Cost

These therapies involve infusions at certified centers and require significant coordination.

• Confirmation: PET or CSF is typically required for treatment eligibility.
• Care Partner: A dedicated care partner is essential for monitoring symptoms and coordinating logistics.
• Cost and Time: The therapies are expensive, and frequent infusions limit travel and flexibility.

Our clinic uses a Dementia Care Navigator to coordinate scheduling, education, and monitoring, and to provide financial counseling to clarify costs.

The Role of Blood-Based Biomarkers: Promise and Practical Use

Plasma A?42/40 ratios, phosphorylated tau species (e.g., p-tau181, p-tau217), GFAP, and NfL are rapidly improving. I explain their use with a “brain biomarker panel” analogy, similar to a cholesterol panel:

• Amyloid measures (A?42/A?40 ratio)
• Tau pathology (p-tau217)
• Neurodegeneration/inflammation (NFL, GFAP)

In our clinic, we use these plasma assays as accessible triage tools. A positive result prompts confirmatory PET or CSF when a decision about DMT eligibility is needed. Incorporating a panel of markers improves classification and aligns care plans with the disease stage.

The Integrative Layer: How Chiropractic and Functional Medicine Fit

Integrative chiropractic care is not a replacement for medications but a complementary pillar that supports neurophysiology, comfort, mobility, and quality of life. Under Dr. Cardenas’s medical oversight, I deploy conservative, patient-specific strategies.

Pain, Posture, and Cognition: The Chiropractic Connection

Chronic pain exacts a cognitive tax through sleep loss, stress, and attentional drain. My clinical observations show that targeted conservative care improves patient participation in therapy and reduces agitation.

• Mechanisms: Pain amplifies sympathetic tone and disrupts slow-wave sleep, harming memory consolidation. Spinal dysfunction alters proprioceptive input, worsening balance.
• Interventions: We use gentle, evidence-informed spinal manipulation, soft tissue techniques, vestibular and oculomotor exercises, and breathing retraining. The result is often fewer nighttime awakenings and safer ambulation.

Autonomic Regulation and Sleep as Cognitive Therapies

• Sleep architecture: Slow-wave sleep supports memory consolidation and glymphatic clearance of metabolites, including A?. Sleep fragmentation impairs this process.
• Our protocol: We use light-exposure timing, activity anchors, temperature optimization, and treatment for sleep apnea. Manual therapy to reduce cervicothoracic tension and improve breathing mechanics complements this approach.

Gait, Balance, and Vestibular Health

Falls and immobility accelerate decline. In our integrative care, vestibular and gait rehab are central.

• Cervical-vestibular integration: We evaluate neck proprioception and eye-head coordination. Gentle cervical care and oculomotor exercises reduce dizziness.
• Strength and dual-task training: Practicing walking while performing simple cognitive tasks builds real-world resilience and supports executive function.
• Home environment: We coordinate home safety assessments to reduce fall risks.

Vascular and Metabolic Health: The Gatekeeper of Symptoms

Cerebrovascular reserve determines when pathology becomes symptomatic. We pair medical management with intensive lifestyle and rehabilitative strategies.

• Medical Management under Dr. Cardenas: Hypertension, diabetes, dyslipidemia, atrial fibrillation, and smoking cessation are addressed.
• Integrative Interventions: We use anti-inflammatory nutrition, glycemic control, and mitochondrial support. Cardiorespiratory fitness and posture correction improve cerebral perfusion.

Personal Injury, Concussion, and Dementia Risk

Our clinic often sees patients with traumatic injuries. We differentiate post-concussive symptoms from neurodegenerative disease, acknowledging that repetitive mild TBI can increase dementia risk. Our workflow includes vestibular, ocular-motor, and cervical spine assessment to reduce cognitive load and prevent misattribution of symptoms.

Putting It All Together: A Patient Journey and Clinical Checklists

Our process is structured and collaborative:

1. Assessment: Symptom onset, functional check, reversible factors.
2. Biomarkers: Plasma triage, then PET or CSF confirmation for DMT decisions.
3. Treatment: ChEI and/or memantine, nonpharmacologic supports.
4. DMT: Eligibility screening, consent, MRI monitoring, and vascular optimization.
5. Rehabilitation: Chiropractic care for pain and autonomic balance, plus PT/OT/SLP as needed.
6. Follow-up: Function-centered metrics, caregiver well-being, and safety updates.

Practical Checklists for Clinicians and Families

• Cognitive and functional screening: Objective cognitive test, mood/sleep screen, ADLs/IADLs inventory, fall risk, and medication review for anticholinergic burden.
• When to order biomarkers: When findings will change management; use plasma for triage and PET/CSF for DMT decisions.
• Symptomatic pharmacology steps: Start with ChEI if appropriate, add memantine in moderate-severe stages, and treat NPS with low-anticholinergic options.
• Nonpharmacologic core: Pain control, sleep optimization, gait/balance rehab, and caregiver education.
• DMT readiness: Confirm A+ status, stage MCI or mild dementia, complete baseline MRI, and establish an ARIA monitoring plan.

My Clinical Observations and Translational Insights

From daily practice at Injury Medical Clinic PA and shared cases, I have observed that:

• When nighttime pain is resolved, agitation and “sundowning” frequently diminish.
• Vestibular stabilization reduces fear of falling and improves community participation.
• Breath training and posture can change daytime alertness more than many expect.
• Small gains—like five more minutes of consolidated sleep—often produce noticeable daytime clarity.
• Patients receiving integrated gait/balance work while starting anti-amyloid therapy tend to maintain community ambulation longer.

Closing Reflections

Alzheimer’s care is most successful when we align accurate biology with compassionate, integrative management. By blending medical precision under Dr. Cardenas’s supervision with conservative rehabilitation, functional medicine, and chiropractic care, we give patients and families a comprehensive path forward. Progress in AD care is real but fragile. It demands precision in diagnosis, humility about effect sizes, and vigilance about safety. The science will continue to evolve, and we promise to evolve with it, explain it clearly, and apply it safely. Our north star remains the same: align every decision with what matters most to the person in front of us.

References

• Ajami, M., et al. (2022). Association between amyloid reduction and cognitive outcomes across anti-amyloid trials: A meta-analysis. Alzheimer’s & Dementia.
• Alber, J., et al. (2019). White matter hyperintensities in vascular contributions to cognitive impairment and dementia. Stroke, 50(11), 3182–3195.
• Alzheimer’s Association. (2025). DetectAD clinical practice guidance for cognitive assessment in primary care and specialty settings. Alzheimer’s & Dementia.
• Ashton, N. J., et al. (2021). Plasma neurofilament light and glial fibrillary acidic protein in Alzheimer’s disease. Nature Medicine.
• Blacker, D., & Albert, M. S. (2006). Neuropsychological testing and biomarkers in the diagnosis of dementia. Alzheimer’s & Dementia, 2(2), 91–98.
• Cummings, J., et al. (2014). Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures. Alzheimer’s Research & Therapy.
• Cummings, J., et al. (2019). Drug development in Alzheimer’s disease: The path to 2025. Alzheimer’s Research & Therapy.
• Cummings, J., et al. (2021). Alzheimer’s disease drug development pipeline: 2021. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 7(1), e12179.
• Cummings, J., et al. (2023). Lecanemab: Appropriate use recommendations. The Journal of Prevention of Alzheimer’s Disease.
• Cummings, J., et al. (2024). Updating ARIA monitoring recommendations for anti-amyloid therapies: Registry-informed guidance. Alzheimer’s & Dementia.
• Dadar, M., et al. (2019). Vascular risk factors and brain atrophy in Alzheimer’s disease. Brain, 142(10), 3132–3149.
• (2021). Aducanumab (Aduhelm) accelerated approval letter. U.S. Food and Drug Administration.
• Fernández-de-Las-Peñas, C., et al. (2022). Manual therapy and musculoskeletal pain in older adults: Evidence and safety. Pain Physician.
• Haavik, H., & Murphy, B. (2012). The role of spinal manipulation in sensorimotor integration and autonomic function. Journal of Manipulative and Physiological Therapeutics.
• Hampel, H., et al. (2021). Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic. Nature Reviews Neurology, 17, 747–766.
• Hansson, O. (2021). Biomarkers for neurodegenerative diseases. Nature Medicine.
• Huang, L. K., et al. (2022). Amyloid-targeting therapies and cognitive outcomes: Interpreting discordance. Journal of Alzheimer’s Disease.
• Jack, C. R., Jr., et al. (2013). Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. The Lancet Neurology, 12(2), 207–216.
• Jack, C. R., Jr., et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562.
• Janelidze, S., et al. (2020). Plasma P-tau217 as a diagnostic and prognostic biomarker in Alzheimer’s disease. JAMA.
• Knopman, D. S., et al. (2021). Aducanumab controversies and evidence standards. JAMA.
• Liang, Y., et al. (2023). Plasma p-tau217 in Alzheimer’s disease: Diagnostic and prognostic value. Nature Medicine, 29, 189–199.
• Livingston, G., et al. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 396(10248), 413–446.
• Macek, P., et al. (2020). Balance training and fall prevention in older adults: Systematic evidence. BMC Geriatrics.
• McCrory, P., et al. (2017). Consensus statement on concussion in sport. British Journal of Sports Medicine, 51(11), 838.
• McKeith, I. G., et al. (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report. Neurology, 89(1), 88–100.
• McKhann, G. M., et al. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the NIA-AA workgroups. Alzheimer’s & Dementia.
• Mintun, M. A., et al. (2021). Donanemab in early Alzheimer’s disease. New England Journal of Medicine.
• Morris, M. C., et al. (2015). MIND diet associated with reduced incidence of Alzheimer’s disease. Alzheimer’s & Dementia.
• Norton, S., et al. (2014). Potential for primary prevention of Alzheimer’s disease: Modifiable risk factors. The Lancet Neurology.
• Palmqvist, S., et al. (2020). Discriminative accuracy of plasma P-tau217 for Alzheimer disease. JAMA.
• Petersen, R. C. (2016). Mild cognitive impairment. Continuum (Minneapolis, Minn).
• Petersen, R. C., et al. (2018). Mild cognitive impairment: Clinical characterization and outcome. Archives of Neurology, 56(3), 303–308.
• Pickar, J. G. (2002). Neurophysiological effects of spinal manipulation. Spine Journal.
• Qaseem, A., et al. (2017). Noninvasive treatments for acute, subacute, and chronic low back pain: ACP guideline. Annals of Internal Medicine.
• Rabin, J. S., et al. (2019). Associations of beta-amyloid with anxiety and depression in preclinical Alzheimer’s disease. JAMA Network Open.
• Rabinovici, G. D., et al. (2019). Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries. JAMA, 321(13), 1286–1294.
• Salloway, S., et al. (2022). Amyloid-related imaging abnormalities in anti-amyloid immunotherapy for Alzheimer’s disease. Alzheimer’s & Dementia, 18(1), 1–10.
• Schindler, S. E., et al. (2019). High-precision plasma A?42/40 predicts current and future brain amyloidosis. Neurology.
• Shumway-Cook, A., & Woollacott, M. (2017). Motor control: Translating research into clinical practice (5th ed.). Lippincott Williams & Wilkins.
• Sims, J. R., et al. (2023). Donanemab efficacy and ARIA safety profile with dosing considerations. JAMA.
• Sperling, R. A., et al. (2023). Amyloid-related imaging abnormalities with anti-amyloid therapies and APOE genotype. Alzheimer’s & Dementia.
• Toga, A. W., et al. (2016). The global burden of dementia: Driving research and care. Nature Reviews Neurology, 12, 3–4.
• van Dyck, C. H., et al. (2023). Lecanemab in early Alzheimer’s disease. New England Journal of Medicine.
• Whittington, M. D., et al. (2023). Cost-effectiveness of anti-amyloid monoclonal antibodies for Alzheimer’s disease. Health Affairs.
• Wilson, R. S., et al. (2013). TDP-43 pathology and cognitive impairment in older persons. JAMA Neurology, 70(11), 1418–1424.
• Xie, L., et al. (2013). Sleep drives metabolite clearance from the adult brain. Science.

SEO tags: Alzheimer’s disease, dementia care, amyloid therapy, lecanemab, donanemab, ARIA, APOE genotype, biomarkers, p-tau217, ATN framework, amyloid PET, CSF biomarkers, cholinesterase inhibitors, memantine, neuropsychiatric symptoms, caregiver support, integrative chiropractic care, functional medicine, vestibular rehabilitation, gait and balance, sleep optimization, pain management, vascular risk, mixed neuropathology, multidisciplinary dementia care, El Paso Texas, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD, Dr. Alex Jimenez DC, evidence-based dementia care, shared decision-making